HK 001
Alternative Names: HK-001 - Hefei HankeMab BiotechnologyLatest Information Update: 28 Feb 2024
At a glance
- Originator Hefei HankeMab Biotechnology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Cancer in China (Parenteral)
- 30 May 2022 Hefei HankeMab Biotechnology has patent protection for HK 001 (Hefei HankeMab Biotechnology website, May 2022)